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     Delaying surgery for patients with a
  previous SARS-CoV-2 infection
Editor
     With at least 28 elective million
    operations delayed during the rst
     three months of the COVID-19 pan-
 demic, the number of patients who
     will require surgery after a previ-
 ous SARS-CoV-2 infection is likely
  to increase rapidly1   . Operating on
    patients with an active periopera-
    tive SARS-CoV-2 infection is now
      known to carry a very high pulmonary
   complication and mortality rate2.
    Urgent information is needed to
    guide whether postponing surgery in
    patients with a previous SARS-CoV-2
    infection leads to a clinical benet,
     and the optimal length of delay.
  The COVIDSurg-Cancer study
     was a prospective cohort study of
   patients undergoing curative elective
  cancer surgery during the COVID-
      19 pandemic up to 24 May 20203.
    We performed a pre-planned sub-
    group analysis of patients undergoing
  surgery with previous SARS-CoV-2
     positive swab that were not suspected
     to have active COVID-19 at the
    time of surgery. Propensity score
     matching was used to match previous
 SARS-CoV-2 swab positive patients
       to patients with no a positive swab test
 in a 1:4 ratio. Multivariable logistic
     regression was used to explore asso-
   ciations of previous SARS-CoV-2
    with rates of postoperative pulmonary
           Table 1 Outcomes of operated patients with a previous SARS-CoV-2 positive swab
     Time from previous SARS-CoV-2 positive swab
  30-day postoperative outcomes
 Previous SARS-CoV-2
    positive swab N = 122
   1 to 2 weeks
  N = 27
   2 to 4 weeks
  N = 60
  > 4 weeks
  N = 35
























                     Previous positive swab is dened as a conrmed SARS-CoV-2 infection by nasopharyngeal swab (qRT-PcR) greater than one week before the day of
               surgery. Postoperative pulmonary complications were dened as pneumonia, acute respiratory distress syndrome or unexpected ventilation. Outcomes
                         were dened up to 30days from the day of surgery with Day 0 as the day of surgery. Full denitions are available in the Appendix.
   complications and death in matched
    groups. Full methodology is available
  in the Appendix.
     Of 122 patients with a previous
   positive SARS-CoV-2 swab, 221%
      ( 27) were operated on withinn =
      2-weeks of diagnosis, 492% (n = 60)
    between 2 and 4 weeks, and 287%
      (n = 35) after 4 weeks. The number
    of infected patients increased dur-
     ing each month of the study period
   (Supplementary Figure 1). Patients
    underwent surgery in 78 hospitals
    from 16 countries, predominantly in
         Italy (n n= 44), UK ( = 28) and Spain
       ( 20). 112 patients with a previousn =
    positive swab were matched to 448
     patients with no positive swab. In
    the propensity score matched model,
   previous SARS-CoV-2 infection was
    associated with increased odds of
  pulmonary complications compared
     to no infection (107% [12/122] ver-
    sus 3 6% [16/448], adjusted odds
    ratio 384, 95% condence interval
    1 051-974, p = 004, Supplemen-
      tary Figure 2). When split by time
     from swab to surgery, both pul-
 monary complications and mortality
      were lowest at least 4weeks after
     notication of a positive swab test
         ( ). However, 71Table 1 3% (87/122) of
      patients had surgery within 4 weeks of
    SARS-CoV-2 infection in this series.
    There are signicant limitations of
     these data, including risk of selection
    bias and a small sample size, mean-
      ing this data should be considered as
     exploratory. Until that time, this data
      provides the rst signal that those with
    a positive SARS-COV-2 swab pre-
    operatively should have their surgery
       delayed for at least 4 weeks after noti-
cation.
    Further research is urgently needed
  to validate these gures in a larger
     series and explore differences in recov-
   ery between asymptomatic SARS-
   CoV-2 and symptomatic COVID-19.
   GlobalSurg-COVIDSurg Week is a
  multi-centre international snapshot
     study planned for October 2020 and
    will explore these research questions
       in detail. At the time of writing there
     are over 1300 centres registered in
   105 countries, with representation
    across all surgical specialties. The
    study protocol and registration are
  available at: globalsurg.org/surgweek/
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 Supporting infor mation
  Additional supporting information
     can be found online in the
   Supporting Information section at
    the end of the article.
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